Genoma transforms the potential of technology into accurate diagnostic tests that bring the future of medicine to the global population.
Genoma is a Swiss company leader in genomics for Precision Medicine which owns one of the largest laboratories for clinical diagnostics and genetic tests development in Europe.
The future of health is precision medicine and genetic tests are paving the way forward.
The pace at which the medical community is moving towards recommending genetic screening to wider segments of the population is gaining momentum.
Non-Invasive Prenatal Testing brings the most advanced genetic technologies into a clinical environment changing the entire approach to pregnancy management and care.
Leaders in science advocate for BRCA1 and BRCA2 genetic screening for every woman above the age of 30 as part of routine medical care.
Genoma has developed one of the largest clinical genetic centers for screening and diagnostic tests in Europe, a high throughput Next-Generation Sequencing (NGS) laboratory.
Sequencing is the determination of the exact order of the base pairs in a segment of DNA. Genoma chose Next-Generation Sequencing (NGS) as it simultaneously sequences millions of DNA fragments for a fast and most comprehensive screening of genes and genomes.
Nowadays, Next-Generation Sequencing (NGS) is one of the most advanced genetic analysis technologies available.
Genoma, the Next Generation Sequencing specialist, is continually investing in R&D to further develop and fully validate its range of genetic tests through use of its proprietary technology in its own laboratories.